Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05122962 · ClinicalTrials.gov registry record
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
A clinical trial of Congenital Heart Disease and Tetralogy of Fallot, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT05122962: Recruiting study of Congenital Heart Disease and Tetralogy of Fallot, sponsored by Mayo Clinic.
NCT05122962 is a study of Congenital Heart Disease and Tetralogy of Fallot that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 469-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05122962, a study of Congenital Heart Disease and Tetralogy of Fallot, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)
Primary Outcome
Right Heart Remodeling measured via right atrial reservoir strain (%).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Remote Heart Rhythm Monitoring
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-10 |
What NCT05122962 shows while recruiting
NCT05122962 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 469-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (36% lower).
The record links to 2 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Remote Heart Rhythm Monitoring is the first listed.
NCT05122962 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05122962 about?
NCT05122962 is a clinical study titled "Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases". This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)
What is the current status of trial NCT05122962?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-11-01. Estimated completion is 2026-10.
What conditions does trial NCT05122962 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Tetralogy of Fallot.
What interventions are being tested in trial NCT05122962?
The interventions under investigation include: Remote Heart Rhythm Monitoring (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05122962?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05122962 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05122962's enrollment target sits among peer trials
300 11th of 63 higher than 51 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
PDA for Kidneys Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI